Merit Medical Systems has announced that both its EmboCube (syringe-loaded embolisation gelatin foam) and Torpedo (uniform, preshaped gelatin foam loaded into a cartridge with optional blunt stylet) devices are now US Food and Drug Administration (FDA)-indicated for the embolisation of blood vessels to occlude blood flow, which helps control bleeding and haemorrhaging in the peripheral vasculature.
According to a press release, EmboCube is the only gelatin foam that is delivered precut and preloaded into a syringe for efficiency and ease of use. Torpedo provides physicians a uniformly preshaped gelatin foam loaded into a cartridge with an optional blunt stylet, removing the need for manual foam shaping, providing fast and easy attachment to the catheter for delivery. EmboCube and Torpedo are made of porcine gelatin and have no ferrous composition, making it safe for use in patients undergoing magnetic resonance imaging (MRI).
“Our embolisation technologies, including the EmboCube and Torpedo devices, are vital parts of Merit’s core business, which delivers physicians quality products that improve the standard of care and confer tangible patient benefits,” commented Fred Lampropoulos, chairman and chief executive officer, Merit Medical. “The new indication for EmboCube and Torpedo accurately conveys its safety and efficacy for blood flow occlusion in adult patients, and the Merit team is excited to commercialise this excellent product accordingly.”
